Pharmaceuticals, Biotechnology and Life Sciences
Vectura Group is moving on with researching and testing its VR647, a drug/device combination to treat asthma in children for the US market.
A swedish oncology company Oasmia Pharmaceutical AB, which works on finding cancer cures for animals and humans, said it would move its veterinary assets to the United States.
Bristol-Myers Squibb said on Thursday that it won’t seek an accelerated approval for the combination of Opdivo plus Yervoy in first-line lung cancer in the U.S.
Abzena has made a deal with a San Diego-based biopharmaceutical company for Abzena’s novel site–specific ThioBridge antibody drug conjugate (ADC) linker technology, which links antibodies and other proteins to drugs. The $300 million worth agreement with the…
Anavex has ensured most of the cash for a U.S. multicentre Phase 2 clinical trial of Rett syndrome treatment Anavex2-73.
Danish biopharmaceutical company, Forward Pharma, has entered a deal with Biogen and certain other parties, regarding a Settlement and License Agreement.
Becton, Dickinson’s (BD’s) new kits that provide an easier method to identify and quantify genetic information in individual cells for genomics-based research, have started selling.
The pharmaceutical industry is typically reluctant to talk about U.S. drug prices, generally the highest in the world due to a combination of market fragmentation and free market policies. But recent high-profile price hikes by Mylan NV, Turing Pharmaceuticals and Valeant Pharmaceuticals International have raised the ire of consumers and lawmakers.
Valneva has given Merck in United States and Canada rights to use its EB66 technology to research new veterinary vaccines.
Israeil’s largest drugmaker Teva Pharmaceuticals Industries has settled with the United States government over international bribery of government officials in…